Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Recurrent Pericarditis · Acute Myocarditis · CRDL

Cardiol Therapeutics

Cardiol Therapeutics is a biotech organization headquartered in Toronto, CA. It trades on NYSE under ticker CRDL. Primary therapeutic focus areas include Recurrent Pericarditis, Acute Myocarditis, Spontaneous Coronary Ar

Website Investor relations
2265 Upper Middle Rd E, Suite 602, Greater Toronto Area, Ontario L6H 0G5, CA HQ
2017 Founded
27 Employees
Public company Type
CRDL · NYSE Ticker
Programs 11 Drugs 31 Patents 15 Trial starts 11 Last 12 months
Company details
Status
Public
HQ
2265 Upper Middle Rd E, Suite 602, Greater Toronto Area, Ontario L6H 0G5, CA
Founded
2017
Employees
27
Programs
11
Drugs
31
Patents
15
Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Cardiol Therapeutics is a biotech organization headquartered in Toronto, CA. It trades on NYSE under ticker CRDL. Primary therapeutic focus areas include Recurrent Pericarditis, Acute Myocarditis, Spontaneous Coronary Artery Dissection., St-Elevated Myocardial Infartion, congestive heart failure. NovaPharmaNews links 11 clinical program(s), 0 drug profile(s), and 15 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (5), phase 2 (3), approved (2).

Company snapshot

ZeCardio Therapeutics (ZeCardioTx) is a pharma company that will change the way we discover cardiovascular drugs.

  • 11 active pipeline program(s) linked via ClinicalTrials.gov.
  • 15 US patent(s) indexed to this assignee profile.
  • 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Cardiol Therapeutics. Not investment advice.

Top assets

View drugs (31) View projects (11)

Lead pipeline drugs

Active clinical programs

  • 100-006 Recurrent Pericarditis
    Phase 3
  • 2.16/VI/22 Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.
    Phase 3
  • CARDIOL 100-03 COVID-19
    Phase 3
  • CCM 1862 congestive heart failure
    Phase 3

Momentum

Proprietary activity score for Cardiol Therapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 4 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Recent activity

Latest pipeline, patent, and corporate events for Cardiol Therapeutics.

  1. Clinical update

    CARDIOL 100-03 — Phase 3

  2. Clinical update

    SEARCH — Phase 2

  3. Clinical update

    CCM 1862 — Phase 3

  4. Clinical update

    BA-SCAD — Approved

  5. Clinical update

    2.16/VI/22 — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Cardiol Therapeutics?

    Cardiol Therapeutics is a biotech organization headquartered in Toronto, CA. It trades on NYSE under ticker CRDL. Primary therapeutic focus areas include Recurrent Pericarditis, Acute Myocarditis, Spontaneous Coronary Artery Dissection., St-Elevated Myocardial Infartion, congesti

  • Is Cardiol Therapeutics publicly traded?

    Yes. Cardiol Therapeutics is listed with ticker CRDL on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does Cardiol Therapeutics develop or market?

    We link 31 drug profile(s) where Cardiol Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cardiol-therapeutics#company-drugs.

  • What are the latest developments for Cardiol Therapeutics?

    In the last 12 months our linked public records show 11 trial program update(s) and 1 US patent grant(s) tied to this profile.

  • What therapeutic areas does Cardiol Therapeutics focus on?

    Cardiol Therapeutics focuses on Recurrent Pericarditis, Acute Myocarditis, Spontaneous Coronary Artery Dissection. based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
17
Cardiology
6
Neurology
1
Infectious Disease
1

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.